Drug Type Small molecule drug |
Synonyms HL + [4] |
Target |
Mechanism Akt-1 inhibitors(Serine/threonine-protein kinase AKT inhibitors), ERK1 inhibitors(Extracellular-signal-regulated kinase1 inhibitors), ERK2 inhibitors(Extracellular-signal-regulated kinase 2 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhasePhase 3 |
First Approval Date- |
Regulation- |
Molecular FormulaC18H18O2 |
InChIKeyFVYXIJYOAGAUQK-UHFFFAOYSA-N |
CAS Registry35354-74-6 |
Start Date01 Nov 2013 |
Sponsor / Collaborator |
Start Date01 Oct 2007 |
Sponsor / Collaborator |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | Honokiol | - | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Nonalcoholic Steatohepatitis | Phase 3 | KR | 01 Nov 2013 | |
Gingival Diseases | Phase 3 | - | - | |
Malignant glioma of brain | Phase 2 | CN | 30 Jan 2022 | |
Meningioma | Phase 2 | CN | 30 Jan 2022 |
Study | Phase | Population | Analyzed Enrollment | Group | Results | Evaluation | Publication Date |
---|
Not Applicable | - | efbmsujepz(fmsaumlacs) = dxwccsfayy gsvchjueuo (kwuztowarg ) | - | 15 Apr 2011 |